months of work
new phase II trial
To increase their clinical positioning options, the client was interested in investigating alternative indications for a drug under development.
Drug target information, genetics, transcriptomics data, and disease-gene associations was combined using our platform, and from this a Mechanism of Action was derived. This was further analysed using sophisticated text mining to identify novel, putative indications.
Among the possible novel indications was one with particular strong signal. It further had strategic relevance for the client. After consulting with Key Opinion Leaders, the client started the work to initiate a phase II trial.
An additional indication for a safe drug increasing the asset value of the drug.